Adriana Matutino Kahn, MD
Assistant Professor of Medicine (Medical Oncology)
Research & Publications
Biography
News
Coauthors
Selected Publications
- Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.
- Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancerSilva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.
- Intratumour heterogeneity, from hypothesis to the clinicShan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.
- CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative diseaseMatutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances In Medical Oncology 2018, 10: 1758835918818346. PMID: 30619511, PMCID: PMC6299331, DOI: 10.1177/1758835918818346.
- The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment.Matutino A, Lewis J, Verma S, Taylor A, Huber S, Chen G. The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment. Journal Of Clinical Oncology 2018, 36: 67-67. DOI: 10.1200/jco.2018.36.7_suppl.67.
- Strategies to mitigate the toxicity of cancer therapeuticsKahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. 2022, 155: 215-244. PMID: 35779875, DOI: 10.1016/bs.acr.2022.02.006.
- Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada.Matutino A, Pereira A, Kornaga E, Lupichuk S, Verma S. Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada. Journal Of Clinical Oncology 2018, 36: e18617-e18617. DOI: 10.1200/jco.2018.36.15_suppl.e18617.
- Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancerKahn A, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Research And Treatment 2023, 201: 289-298. PMID: 37378695, DOI: 10.1007/s10549-023-06977-1.
- Outcomes of acute pulmonary embolism in hospitalized patients with cancer.Shalaby K, Kahn A, Silver ES, Kim MJ, Balakumaran K, Kim AS. Outcomes of acute pulmonary embolism in hospitalized patients with cancer. BMC Pulm Med 2022, 22: 11. PMID: 34986814, DOI: 10.1186/s12890-021-01808-9.
- Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status.Savard MF, Kornaga EN, Kahn AM, Lupichuk S. Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status. Curr Oncol 2022, 29: 383-391. PMID: 35049708, DOI: 10.3390/curroncol29010034.
- Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab.Lima G, Kahn A, Sama S, Savage J. Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. Case Rep Oncol Med 2019, 2019: 7183747. PMID: 31781445, DOI: 10.1155/2019/7183747.
- Clinical characteristics and survival of lung cancer patients according to insurance status prior to and post implementation of the Affordable Care Act.Matutino A, Pereira A, Kornaga E, Lopes G, Bebb D, Verma S. Clinical characteristics and survival of lung cancer patients according to insurance status prior to and post implementation of the Affordable Care Act. Journal Of Clinical Oncology 2018, 36: e18607-e18607. DOI: 10.1200/jco.2018.36.15_suppl.e18607.
- Abstract P2-08-13: Survival in women with de novo metastatic breast cancer: Comparison of real-world evidence from publicly-funded Canadian province and the United States by insurance statusKornaga E, Matutino A, Pereira A, Verma S, Lupichuk S. Abstract P2-08-13: Survival in women with de novo metastatic breast cancer: Comparison of real-world evidence from publicly-funded Canadian province and the United States by insurance status. Cancer Research 2019, 79: p2-08-13-p2-08-13. DOI: 10.1158/1538-7445.sabcs18-p2-08-13.
- 40P Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance statusMatutino A, Kornaga E, Dean M, Pereira A, Bebb G. 40P Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status. Journal Of Thoracic Oncology 2018, 13: s22-s23. DOI: 10.1016/s1556-0864(18)30320-4.
- Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective AnalysisMatutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Fraile N, Guimarães R, Gabrielli F, Vasconcelos K, de A. Carvalho H, de Castro G. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. Journal Of Global Oncology 2017, 4: jgo.17.00059. PMID: 30241202, PMCID: PMC6181177, DOI: 10.1200/jgo.17.00059.
- Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the CommunityProtásio B, Matutino A, Lage L, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann R, Hoff P. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer 2016, 16: 65-72. PMID: 27515842, DOI: 10.1016/j.clcc.2016.07.001.
- Metaplastic breast cancer: A single-institution experience.Silva A, Linck R, Lima J, Matutino A, Silva S, Vicentini M, Felizola M, Gagliato D, Hoff P, Mano M. Metaplastic breast cancer: A single-institution experience. Journal Of Clinical Oncology 2016, 34: e12575-e12575. DOI: 10.1200/jco.2016.34.15_suppl.e12575.
- Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to DenosumabFraile N, Toloi D, Kurimori C, Matutino A, Codima A, Camargo V, Feher O, Munhoz R. Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab. Case Reports In Oncological Medicine 2015, 2015: 626741. PMID: 26600960, PMCID: PMC4639671, DOI: 10.1155/2015/626741.
- Câncer de mama: efeito prognóstico da resposta patológica completa após quimioterapia neoadjuvanteVaisberg V, Vilas Boas M, Stephan B, Matutino A, Lima J, Mano M. Câncer de mama: efeito prognóstico da resposta patológica completa após quimioterapia neoadjuvante. Revista De Medicina 2015, 94: 31-31. DOI: 10.11606/issn.1679-9836.v94isupl.p31-31.
- 1959 Neoadjuvant chemotherapy for elderly breast cancer patientsMatutino A, Lima J, Silva S, Boas M, Stephan B, Van Vairsberg V, Fraile N, Barroso-Sousa R, Mano M. 1959 Neoadjuvant chemotherapy for elderly breast cancer patients. European Journal Of Cancer 2015, 51: s319. DOI: 10.1016/s0959-8049(16)30907-8.
- 1958 Correlation between body mass index and pathologic complete response after neoadjuvant chemotherapy for locally advanced breast cancerLima J, Matutino A, Silva S, Silva-Junior A, Boas M, Stephan B, Van Vairsberg V, Pereira A, Barroso-Sousa R, Mano M. 1958 Correlation between body mass index and pathologic complete response after neoadjuvant chemotherapy for locally advanced breast cancer. European Journal Of Cancer 2015, 51: s319. DOI: 10.1016/s0959-8049(16)30906-6.
- 3052 Prophylactic cranial irradiation for extensive stage small cell lung cancerMatutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Guimaraes R, Gabrielli F, da Conceiçãao Vasconcelos K, Carvalho H, Castro-Junior G. 3052 Prophylactic cranial irradiation for extensive stage small cell lung cancer. European Journal Of Cancer 2015, 51: s613. DOI: 10.1016/s0959-8049(16)31694-x.
- Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community.Protasio B, Matutino A, Lage L, De Santana I, Ramos R, Caires-Lima R, Caires I, Riechelmann R, Saragiotto D, Sabbaga J, Hoff P. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal Of Clinical Oncology 2015, 33: 760-760. DOI: 10.1200/jco.2015.33.3_suppl.760.
- Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial—authors' responseVilas-Boas A, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial—authors' response. Journal Of Antimicrobial Chemotherapy 2014, 70: 636-638. PMID: 25362570, DOI: 10.1093/jac/dku440.
- 1391P Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in BrazilIsaacsson P, Teixeira M, Scaranti M, Matutino A, Negrao M, Fraile N, Souza K, Yen C, Pinheiro G, Hoff P, G.C.. 1391P Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in Brazil. Annals Of Oncology 2014, 25: iv487. DOI: 10.1093/annonc/mdu353.5.
- Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trialVilas-Boas A, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Vilar T. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial. Journal Of Antimicrobial Chemotherapy 2014, 69: 1954-1959. PMID: 24648506, DOI: 10.1093/jac/dku070.
- Differences in evolution of children with non-severe acute lower respiratory tract infection with and without radiographically diagnosed pneumoniaFontoura M, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Araújo-Neto C, Andrade S, Brim R, Cardoso M, Nascimento-Carvalho C, Pneumopac-Efficacy Study Group. Differences in evolution of children with non-severe acute lower respiratory tract infection with and without radiographically diagnosed pneumonia. Indian Pediatrics 2012, 49: 363-369. PMID: 22080618, DOI: 10.1007/s13312-012-0085-6.
- Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillinFontoura M, Araújo-Neto C, Andrade S, Brim R, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Santos P, Noblat L, Cardoso M, Nascimento-Carvalho C, Group T. Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillin. Expert Opinion On Pharmacotherapy 2010, 11: 1451-1458. PMID: 20408745, DOI: 10.1517/14656561003777034.